🔗 Share this article

As the US proceeds with historic changes to its vaccination schedules, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning Covid vaccines throughout the pandemic and has zeroed in on alleged fatalities after COVID-19 vaccination in her recent position at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Schedule

Agency leaders were set to unveil major changes to the pediatric vaccine schedule recently, bringing the US with the Danish vaccine program, it is understood – a significant shift that would put the US at odds with much of the international standard with no evidence for improved outcomes. The planned update has been delayed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is set to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric shot schedules in the US to become more like Denmark, a nation with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on vaccination policy – usually the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Qualifications

Høeg has little discernible background in pharmaceutical research, approval processes or leadership, which has been standard for former heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for running the CDER, said Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a large organization. She lacks background in industry regulation.”

Past directors of the center would “understand legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who ran CBER have had.”

The drug center has an immense portfolio at the FDA, the former commissioner pointed out.

“The public just zeroes in on the new drug program, but the generic drug division authorizes numerous generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and all of those have to be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership aspect to the position, which manages over 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” she said.

Response and Contentious Initiatives

In response to concerns about Dr. Høeg's credentials and whether this appointment signifies more teamwork among FDA leaders on vaccines, a representative responded that the “concerns rely on flawed assumptions”.

“Her experience matches the functions of her position,” the official explained, noting the time Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited drug-approval program that reportedly troubled her predecessors. “How are these therapies being chosen for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

Overall, he remarked, “the FDA appears to be shifting towards laxer rules of all drugs, with the exception of shots.”

Public History on Immunizations

Regarding immunizations, Høeg has a more documented, if concerning, past, critics have noted. She authored a research paper using unconfirmed public submissions to assess the incidence of myocarditis after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership featured changing regulations for novel immunizations and halting “non-essential” vaccines, she remarked post-election on a online show. At the agency, Høeg has allegedly proposed preventing young men from getting Covid vaccinations.

“She is an all-around true believer who begins with her preconceived notions and tailors the evidence to retrofit the data in a highly deceptive, dishonest way,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other dissenters, {like|